4D Molecular Therapeutics (FDMT) Operating Margin (2020 - 2025)
Historic Operating Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to 67983.33%.
- 4D Molecular Therapeutics' Operating Margin rose 16364166700.0% to 67983.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 191982.5%, marking a year-over-year increase of 7984645600.0%. This contributed to the annual value of 507678.38% for FY2024, which is 5071337300.0% down from last year.
- 4D Molecular Therapeutics' Operating Margin amounted to 67983.33% in Q3 2025, which was up 16364166700.0% from 396373.33% recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Operating Margin ranged from a high of 192905.26% in Q4 2023 and a low of 5611700.0% during Q4 2024
- Moreover, its 5-year median value for Operating Margin was 13446.03% (2023), whereas its average is 475592.34%.
- Its Operating Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2024, then soared by 2000000000bps in 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Operating Margin (Quarter) stood at 26917.39% in 2021, then surged by 91bps to 2303.13% in 2022, then surged by 8476bps to 192905.26% in 2023, then tumbled by -3009bps to 5611700.0% in 2024, then soared by 99bps to 67983.33% in 2025.
- Its Operating Margin was 67983.33% in Q3 2025, compared to 396373.33% in Q2 2025 and 383007.14% in Q1 2025.